View Post

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

In In The News by Barbara Jacoby

From: Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain’s state-funded health service. The National Institute for Health and Care Excellence (NICE), the country’s cost-effectiveness agency, said on Thursday the two drugs were being recommended despite uncertainty about how long they extend overall …